Latest / Early Edition with Ryan Bridge / Malcolm Mulholland: Patient Voice Aotearoa Chair on the new expectations for Pharmac

Transcript

Malcolm Mulholland: Patient Voice Aotearoa Chair on the new expectations for Pharmac · Early Edition with Ryan Bridge

• 0:00
  Speaker 1: David Seymour has released his Letter of Expectations for farm Act.
• 0:04
  Speaker 1: Following a significant funding boost, the drug buying agency has
• 0:08
  Speaker 1: been told it needs to deliver improved health outcomes underpinned
• 0:11
  Speaker 1: by robust data and evidence. Seymour has also told FARMAC
• 0:16
  Speaker 1: to halt the embedding of tetentity or white hanging in
• 0:19
  Speaker 1: its decision making.
• 0:20
  Speaker 2: If it treats me different New Zealand's differently based on
• 0:23
  Speaker 2: whether or not they had an ancestor who was Mari,
• 0:26
  Speaker 2: then we want nothing to do with it.
• 0:28
  Speaker 1: Malcolm R. Holland is the chair of the Patient Voice
• 0:30
  Speaker 1: outed our group and joins me now, Malcolm, welcome to
• 0:33
  Speaker 1: the program. First of all, this treaty exclusion does that
• 0:36
  Speaker 1: bother you?
• 0:38
  Speaker 2: No, it doesn't. There was never any evidence that by
• 0:41
  Speaker 2: having treaty provisions within farmac's decision making process that led
• 0:47
  Speaker 2: to MARDI access in more medicines. It was very unclear
• 0:50
  Speaker 2: as to how it was being used, so it made
• 0:53
  Speaker 2: from our perspective, no material difference.
• 0:56
  Speaker 1: Apart from that, what is new in this What gives
• 0:59
  Speaker 1: you hope that this is going to lead to actual change?
• 1:03
  Speaker 2: It is a number of things, probably in particular is
• 1:07
  Speaker 2: around looking at famic's dietritory objectives, So whether or not
• 1:12
  Speaker 2: they need to retain reference to FARMAC having a MILEFIC
• 1:18
  Speaker 2: process if you like, on cost containment, looking at the
• 1:22
  Speaker 2: health technology assessment process in for FARMAC to consider some
• 1:27
  Speaker 2: of the savings that can occur within the health system
• 1:29
  Speaker 2: and to the wider taxpayer as they found a particular medicine,
• 1:33
  Speaker 2: and also looking at the separation of roles between FARMAC
• 1:36
  Speaker 2: is a procurement agency as well as the Health Technology
• 1:39
  Speaker 2: Assessment Agency as well.
• 1:41
  Speaker 1: Okay, so there's stuff in there that gives you a
• 1:43
  Speaker 1: bit of hope. How do you think FARMAC will respond
• 1:46
  Speaker 1: to this? Do you think that they're up to the job.
• 1:50
  Speaker 2: Well, it was interesting being there yesterday. Certainly, the conversations
• 1:54
  Speaker 2: that we had with FAMAIC staff, they seemed overall positive.
• 1:58
  Speaker 2: You know, I believe there was a bit of reluctance
• 2:00
  Speaker 2: around the TRITI aspect of the leader of expectations, but
• 2:04
  Speaker 2: overall I think they know that change is happening and
• 2:07
  Speaker 2: that it needs to happen.
• 2:09
  Speaker 1: Welcome R. Holland's Patient Advocate. Thank you very much for
• 2:11
  Speaker 1: your time this morning. Chair of Patient Voice Out had
• 2:13
  Speaker 1: eye for more from News Talks ed B listen live
• 2:17
  Speaker 1: on air or online, and keep our shows with you
• 2:20
  Speaker 1: wherever you go with our podcasts on Irradio